Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
- R. Kahn, W. Fleischhacker, D. Grobbee
- Psychology, MedicineThe Lancet
- 29 March 2008
[Gender differences in schizophrenia].
- M. Plocka, J. Rybakowski
- Psychology, MedicinePsychiatria Polska
- 1 September 1992
The authors conclude that most male schizophrenic patients display poorer premorbid functioning during the early stages of the illness. They more often display structural micro-abnormalities of the…
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders.
- I. Pacchiarotti, D. Bond, E. Vieta
- Psychology, MedicineAmerican Journal of Psychiatry
- 1 November 2013
A consensus was reached on 12 statements on the use of antidepressants in bipolar disorder, and antidepressants should be prescribed only as an adjunct to mood-stabilizing medications.
Indicators of immune activation in major depression
- A. Sluzewska, J. Rybakowski, K. Wiktorowicz
- Medicine, BiologyPsychiatry Research
- 16 October 1996
Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind…
Higher efficacy results were observed with agomelatine as compared to sertraline on both depressive and anxiety symptoms over the 6-week treatment period, together with a good tolerability profile.
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).
- M. Davidson, S. Galderisi, R. Kahn
- Psychology, MedicineAmerican Journal of Psychiatry
- 1 June 2009
Treatment with antipsychotic medication is associated with moderate improvement in the cognitive test performance of patients who have schizophreniform disorder or who are in their first episode of schizophrenia.
The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness.
- J. Rybakowski, K. Twardowska
- Psychology, MedicineJournal of Psychiatric Research
- 1 September 1999
Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients.
- M. Dmitrzak-Węglarz, J. Rybakowski, J. Hauser
- Biology, PsychologyPharmacogenomics (London)
- 20 November 2008
A relationship between response to lithium prophylaxis and polymorphisms of two functionally connected genes: BDNF and NTRK2, in bipolar illness is described.
Determinants of objective and subjective quality of life in first-time-admission schizophrenic patients in Poland: a longitudinal study
- K. Górna, K. Jaracz, F. Rybakowski, J. Rybakowski
- Psychology, MedicineQuality of Life Research
- 1 March 2008
Because psychopathology seems to have the greatest impact on the QoL, there is a need to develop community psychosocial treatment to reduce these symptoms and to support patients in the early phase of the disease.
Polymorphism of the brain-derived neurotrophic factor gene and performance on a cognitive prefrontal test in bipolar patients.
- J. Rybakowski, A. Borkowska, P. Czerski, M. Skibińska, J. Hauser
- Medicine, PsychologyBipolar Disorders
- 1 December 2003
The performance on a neurocognitive test, the Wisconsin Card Sorting Test (WCST), was significantly better in subjects with Val/Val BDNF genotype compared withVal/Met genotype, suggesting a role of BDNF in prefrontal cognitive function in bipolar illness.
...
...